Related Experiment Videos
Nonsteroidal antiestrogens and partial estrogens with prostatic tumor inhibiting activity
Journal of Cancer Research and Clinical Oncology
|January 1, 1986
Summary
New antiestrogen and partial estrogen compounds show strong prostate tumor inhibition. These compounds may offer a safer alternative to conventional prostate cancer therapies due to potentially fewer estrogenic side effects.
Area of Science:
- Pharmacology
- Oncology
- Endocrinology
Background:
- Prostate carcinoma is a hormone-dependent malignancy.
- Current therapies like castration or diethylstilbestrol (DES) can cause significant side effects.
- Novel therapeutic agents with improved safety profiles are needed.
Purpose of the Study:
- To evaluate the potential prostatic tumor inhibiting activity of novel antiestrogens and partial estrogens.
- To compare the efficacy of these compounds with established treatments.
- To investigate the mechanism of action, including receptor binding and hormonal effects.
Main Methods:
- Testing of stilbene (1 and 4), triphenylbutene (2), and diphenylethane (3) derivatives for anti-prostatic tumor effects in rats and mice.
- Assessment of effects on prostate and seminal vesicle weight.
- Evaluation of tumor inhibiting activity on the R 3327 Dunning prostatic carcinoma.
- In vitro receptor binding assays for estrogen, androgen, and progesterone receptors.
- Assessment of direct antiandrogenic effects in castrated, testosterone-substituted animals.
Main Results:
- Compounds 1 and 2 demonstrated significant inhibition of prostate and seminal vesicle weight in intact animals.
- Compounds 1 and 2 exhibited strong tumor inhibiting activity against the R 3327 Dunning prostatic carcinoma, comparable to castration or DES.
- Compounds 3 and 4 showed minimal or no inhibitory effects.
- Compounds 1-4 displayed good affinity for the estrogen receptor but lacked direct antiandrogenic effects or affinity for androgen/progesterone receptors.
- Compounds 1 and 2 possess significantly lower estrogenic properties than DES.
Conclusions:
- Compounds 1 and 2 are potent inhibitors of prostate tumor growth.
- Their efficacy, combined with reduced estrogenic activity compared to DES, suggests potential as a novel therapeutic strategy for prostate carcinoma.
- These compounds may offer a more tolerable alternative to current treatments, minimizing estrogen-related side effects.